Glenn Jay Jaffe

I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same …

Current Appointments & Affiliations

Robert Machemer M.D. Distinguished Professor of Ophthalmology · 2013 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

Professor of Ophthalmology · 1998 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

Chief, Division of Retinal Ophthalmology · 2008 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

In the News

Published September 8, 2016

Humira Provides Effective, Non-Steroid Alternative for Eye Inflammation

View All News

Recent Publications

Corrigendum to "Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity" [Am J Ophthalmol 2020;219:87-100].

Journal Article Am J Ophthalmol · March 7, 2025 Full text Link to item Cite

Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.

Journal Article Ophthalmol Retina · February 25, 2025 PURPOSE: To compare the development of macular atrophy (MA) in eyes treated with the Port Delivery System with ranibizumab (PDS) with those treated with monthly intravitreal ranibizumab injections in the Archway trial. DESIGN: Preplanned exploratory analys ... Full text Link to item Cite

MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.

Journal Article Ophthalmology · February 2025 PURPOSE: To report the safety and efficacy of brolucizumab (Beovu) 6 mg versus aflibercept (Eylea) 2 mg administered every 4 weeks in participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid after the week 52 up to ... Full text Link to item Cite

View All Publications

Recent Grants

A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)

ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2022 - 2029

Ora_Sepul_DRC Ph3 Study of Sepofarsen in Subjects with Leber Congential Amaurosis (LCA)_HYPERION

ResearchPrincipal Investigator · Awarded by Ora LLC · 2024 - 2029

Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)

ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2017 - 2028

View All Grants

Education, Training & Certifications

University of California San Francisco, School of Medicine · 1983 M.D.